Hypercholesterolemia is one of the major risk factors of cardiovascular diseases. Over time, the excess of blood cholesterol, in particular LDL-cholesterol, weakens and induces artery stenosis. This “atherosclerosis” contributes to the onset of serious diseases such as myocardial infarctus, stroke and arteritis in the lower limbs.
Today, hypercholesterolemia affects almost 30% of the French and American adult population.Treatment is based on making lifestyle changes, combined with prescribed drugs for patients with a high risk of cardiovascular disease.
For patients classified as medium-risk, there are few non-drug preventive treatment options available. At the current time, food products containing phytosterols are most commonly used.
Sources: De Peretti C et al., Étude nationale nutrition santé (ENNS) 2006-2007;
Center for disease control, 2018;
Benjamin EJ et al., American Heart Association. Circulation. 2017;
US Preventive Services Task Force, Final Recommendation Statement, JAMA, 2016.
g/L: this is the normal level of LDL-cholesterol in the blood. If levels are above this, LDL-hypercholesterolemia is diagnosed and the risk of cardiovascular diseases increases.
reduction in LDL-cholesterol levels in the blood in hypercholesterolemic patients reduces the risk of cardiac diseases by 50% over 5 years.
Source: WHO, Global Health Observatory (GHO)
VAL-070 is a combination of 4 food plant extracts, with no phytosterol or red yeast rice content, for which a patent has been filed in 60 countries. The composition of VAL-070 results from research in analytical chemistry aiming to optimize the components, followed by intensive screening on preclinical models predictive of human physiopathology.
It was developed to reduce the levels of LDL-cholesterol in the blood and improve the lipid profile of patients with mild to moderate hypercholesterolemia.
It is an exclusive product for which the company aims to obtain a proprietary health claim relating to the reduction of LDL-cholesterol in the blood, a risk factor of cardiovascular diseases.
The Phase I/II clinical study completed in July 2018 demonstrated the safety and tolerance of VAL-070.
This pilot study also validated the methodological criteria required to design the Phase II studies: main criterion, patient profile to be included and population size.
These studies should demonstrate the efficacy of VAL-070 on the reduction of LDL-cholesterol levels in the blood.